EGFR敏感突变非小细胞肺癌脑转移患者临床特征综述

doi:10.3760/cma.j.cn113030-20200921-00474

摘要
图/表
参考文献(39)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要晚期非小细胞肺癌(NSCLC)常常合并脑转移,预后和生活质量较差。表皮生长因子受体(EGFR)是常见NSCLC的敏感基因突变类型,与其他分子类型相比,具有不同的分子生物学特征。随着靶向药物的广泛使用,EGFR敏感突变NSCLC脑转移的预后及颅内外控制有很大提高。为了更好地认识EGFR敏感突变NSCLC脑实质转移的特点,本文从脑转移的发病率、发病时间、发病部位、病灶数目及大小、发病症状、靶向治疗疗效和疾病转归等方面综述了EGFR突变阳性NSCLC脑实质转移的临床特征及治疗,为脑实质转移局部治疗的介入时机以及局部治疗技术选择提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱以香
	张烨

关键词 ：癌,非小细胞肺, 脑转移, 表皮生长因子受体, 临床特征

Abstract：Advanced non-small cell lung cancer (NSCLC) patients are commonly with brainmetastases, leading to poor survival and quality of life. Epidermal growth factor receptor (EGFR) is common sensitive mutation type in NSCLC. Compared with other molecular types, it has different molecular biological characteristics. For patients with brain metastases and EGFR-mutated advanced NSCLC, EGFR-tyrosine kinase inhibitors can prolong overall survival and improve intracranial and extracranial control rate. To understand the characteristics of brain metastases of patients with sensitively EGFR-mutated NSCLC, the incidence, onset time, site, number and size of lesions, symptoms, targeted treatment effect and disease outcomes were reviewed, which can provide reference for interventional timing and local treatment technology selection of local treatment for brain parenchymal metastases.

Key words： Carcinoma, non-small-cell lung Brain metastasis Epidermal growth factor receptor Clinical feature

收稿日期: 2020-09-21

通讯作者: 张烨,Email:drzye1983@163.com

引用本文:

朱以香,张烨. EGFR敏感突变非小细胞肺癌脑转移患者临床特征综述[J]. 中华放射肿瘤学杂志, 2022, 31(5): 468-472.

Zhu Yixiang,Zhang Ye. Clinical features of patients with EGFR mutation-positive non-small cell lung cancer and brain metastases[J]. Chinese Journal of Radiation Oncology, 2022, 31(5): 468-472.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200921-00474 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I5/468

[1] Smedby KE, Brandt L, Bäcklund ml, et al. Brain metastases admissions in sweden between 1987 and 2006[J]. Br J Cancer, 2009, 101(11):1919-1924. DOI:10.1038/sj.bjc.6605373.
[2] Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma[J]. Cancer, 2002, 94(10):2698-2705. DOI:10.1002/cncr.10541.
[3] Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases:analysis of 975 patients with early stage nonsmall cell lung cancer[J]. Cancer, 2010, 116(21):5038-5046. DOI:10.1002/cncr.25254.
[4] Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking[J]. Br J Cancer, 2006, 94(6):896-903. DOI:10.1038/sj.bjc.6603040.
[5] Varghese AM, Sima CS, Chaft JE, et al. Lungs don't forget:comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers[J]. J Thorac Oncol, 2013, 8(1):123-125. DOI:10.1097/JTO.0b013e31827914ea.
[6] Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer, 2007, 7(3):169-181. DOI:10.1038/nrc2088.
[7] Iuchi T, Shingyoji M, Itakura M, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations[J]. Int J Clin Oncol, 2015, 20(4):674-679. DOI:10.1007/s10147-014-0760-9.
[8] Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers[J]. Lung Cancer, 2015, 88(1):108-111. DOI:10.1016/j.lungcan.2015.01.020.
[9] Hendriks LE, Smit EF, Vosse BA, et al. EGFR mutated non-small cell lung cancer patients:more prone to development of bone and brain metastases?[J]. Lung Cancer, 2014, 84(1):86-91. DOI:10.1016/j.lungcan.2014.01.006.
[10] Li L, Luo S, Lin H, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer[J]. J Thorac Dis, 2017, 9(8):2510-2520. DOI:10.21037/jtd.2017.07.57.
[11] Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21):2129-2139. DOI:10.1056/NEJMoa040938.
[12] Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naiveepidermal growth factor receptor-mutant non-small-cell lung cancer:a retrospective multi-institutional analysis[J]. J Clin Oncol, 2017, 35(10):1070-1077. DOI:10.1200/JCO.2016.69.7144.
[13] Yang B, Lee H, Um SW, et al. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations[J]. Lung Cancer, 2019, 129:28-34. DOI:10.1016/j.lungcan.2018.12.027.
[14] Hsu F, De Caluwe A, Anderson D, et al. EGFR mutation status on brain metastases from non-small cell lung cancer[J]. Lung Cancer, 2016, 96:101-107. DOI:10.1016/j.lungcan.2016.04.004.
[15] Wang BX, Ou W, Mao XY, et al. Impacts of EGFR mutation and EGFR-TKIS on incidence of brain metastases in advanced non-squamous NSCLC[J]. Clin Neurol Neurosurg, 2017, 160:96-100. DOI:10.1016/j.clineuro.2017.06.022.
[16] Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage ⅠV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib[J]. J Thorac Oncol, 2018, 13(11):1717-1726. DOI:10.1016/j.jtho.2018.07.001.
[17] Digumarthy SR, Mendoza DP, Lin JJ, et al. Computed tomography imaging features and distribution of metastases in ros1-rearranged non-small-cell lung cancer[J]. Clin Lung Cancer, 2020, 21(2):153-159.e3. DOI:10.1016/j.cllc.2019.10.006.
[18] Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations[J]. Clin Cancer Res, 2012, 18(16):4406-4414. DOI:10.1158/1078-0432.CCR-12-0357.
[19] Schuler M, Wu YL, Hirsh V, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases[J]. J Thorac Oncol, 2016, 11(3):380-390. DOI:10.1016/j.jtho.2015.11.014.
[20] Summary of product characteristics[EB/OL].[2018-06-15] https://www.ema.europa.eu/documents/productinformation/tagrisso-epar-product-information_en.pdf.
[21] Han G, Bi J, Tan W, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma:is EGFR mutation associated with a higher incidence of brain metastasis?[J]. Oncotarget, 2016, 7(35):56998-57010. DOI:10.18632/oncotarget.10933.
[22] Lin CY, Chang CC, Su PL, et al. Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC[J]. Medicine (Baltimore), 2019, 98(33):e16766. DOI:10.1097/MD.0000000000016766.
[23] Baek MY, Ahn HK, Park KR, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer[J]. Korean J Intern Med, 2018, 33(1):168-175. DOI:10.3904/kjim.2015.158.
[24] Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer[J]. Neuro Oncol, 2010, 12(11):1193-1199. DOI:10.1093/neuonc/noq076.
[25] Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2010, 16(23):5873-5882. DOI:10.1158/1078-0432.CCR-10-1588.
[26] 张永芹, 孙秀锦, 左云, 等. 肺癌脑转移患者中不同EGFR突变状态下的临床及影像学特点[J]. 临床神经外科杂志, 2018, 15(3):179-183. DOI:10.3969/j.issn.1672-7770.2018.03.005.
Sun TQ, Sun XJ, Zuo Y, et al. Clinical and imaging features between different EGFR mutation patients with brain metastasis from lung[J]. J Clin Neurosurg,2018,15(3):179-183. DOI:10.3969/j.issn.1672-7770.2018.03.005.
[27] 吴俊兰, 范兴文, 王洪兵, 等. EGFR突变肺癌患者脑转移空间分布特征及海马转移风险分析[J]. 中华放射肿瘤学杂志, 2019, 28(11):817-820. DOI:10.3760/cma.j.issn.1004-4221.2019.11.004.
Wu JL, Fan XW, Wang HB, et al. A analysis of the spatial distribution characteristics of brain metastasis and the risk of hippocampus metastasis in patients with EGFR mutant lung cancer[J]. Chin J Radiat Oncol,2019,28(11):817-820. DOI:10.3760/cma.j.issn.1004-4221.2019.11.004.
[28] Takano K, Kinoshita M, Takagaki M, et al. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor[J]. Neuro Oncol, 2016, 18(5):716-724. DOI:10.1093/neuonc/noV266.
[29] Sekine A, Kato T, Hagiwara E, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations:distinguishing influence of exon 19deletion on radiographic features[J]. Lung Cancer, 2012, 77(1):64-69. DOI:10.1016/j.lungcan.2011.12.017.
[30] Yang JJ, Zhou C, Huang Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN):a multicentre, phase 3, open-label, parallel, randomised controlled trial[J]. Lancet Respir Med, 2017, 5(9):707-716. DOI:10.1016/S2213-2600(17)30262-X.
[31] Dong K, Liang W, Zhao S, et al. Egfr-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases[J]. Transl Lung Cancer Res, 2019, 8(3):268-279. DOI:10.21037/tlcr.2019.06.12.
[32] Wang C, Lu X, Lyu Z, et al. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation:a meta-analysis[J]. Lung Cancer, 2018, 122:94-99. DOI:10.1016/j.lungcan.2018.05.014.
[33] Ho GF, Chai CS, Alip A, et al. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC:a multicenter observational study[J]. BMC Cancer, 2019, 19(1):896. DOI:10.1186/s12885-019-6107-1.
[34] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR t790m-positive lung cancer[J]. N Engl J Med, 2017, 376(7):629-640. DOI:10.1056/NEJMoa1612674.
[35] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2):113-125. DOI:10.1056/NEJMoa1713137.
[36] Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018:JCO2018783118. DOI:10.1200/JCO.2018.78.3118.
[37] Yang JCH, Wu YL, Hirsh V, et al. Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, 7[J]. J Thorac Oncol, 2018;13(4, suppl):84–85. DOI:10.1016/S1556-0864(18)30417-9.
[38] Miyawaki E, Kenmotsu H, Mori K, et al. Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases[J]. Int J Radiat Oncol Biol Phys, 2019, 104(3):604-613. DOI:10.1016/j.ijrobp.2019.02.051.
[39] Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC:pooled data from two phase Ⅱ trials[J]. Ann Oncol, 2018, 29(3):687-693. DOI:10.1093/annonc/mdx820.